ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized Controlled Trial Comparing Two Timing Regimens of Pico-salax for Colon Cleansing Prior to Colonoscopy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00885274
Recruitment Status : Completed
First Posted : April 21, 2009
Last Update Posted : August 31, 2015
Sponsor:
Information provided by (Responsible Party):
Dr. Lawrence Hookey, Queen's University

Brief Summary:
Pico-Salax is an osmotic and stimulant bowel cleansing agent used prior to colonoscopy. It is unknown whether splitting the doses (i.e. taking the second dose the morning of the colonoscopy) results in a better bowel cleansing, as research with other agents suggests this may be the case. This study aims to assess whether splitting the dose of Pico-Salax results in a better bowel cleansing than traditional dosing.

Condition or disease Intervention/treatment Phase
Colonoscopy Drug: Pico-Salax Drug: Split Dose Pico-Salax Phase 4

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: A Randomized Controlled Trial Comparing Two Timing Regimens of Pico-salax for Colon Cleansing Prior to Colonoscopy.
Study Start Date : November 2008
Actual Primary Completion Date : March 2011
Actual Study Completion Date : August 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Colonoscopy

Arm Intervention/treatment
Experimental: Split Dose
Doses of Pico-Salax split: one dose administered the night prior to colonoscopy and the other dose administered the day of the procedure.
Drug: Split Dose Pico-Salax
One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.

Active Comparator: Traditional Dose
Both doses of Pico-Salax taken the evening prior to colonoscopy.
Drug: Pico-Salax
Both doses of Pico-Salax taken the evening prior to colonoscopy




Primary Outcome Measures :
  1. bowel cleansing assessed by the Ottawa Bowel Preparation Scale [ Time Frame: day of colonoscopy ]

Secondary Outcome Measures :
  1. patient tolerance of preparation [ Time Frame: day of colonoscopy ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • colonoscopy indicated

Exclusion Criteria:

  • congestive heart failure
  • ascites
  • renal failure
  • hyponatremia
  • previous intestinal surgery

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00885274


Locations
Canada, Ontario
Hotel Dieu Hospital
Kingston, Ontario, Canada, K7L 5G2
Sponsors and Collaborators
Queen's University
Investigators
Principal Investigator: Lawrence Hookey, MD Queen's University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr. Lawrence Hookey, Assistant professor of Medicine, Queen's University
ClinicalTrials.gov Identifier: NCT00885274     History of Changes
Other Study ID Numbers: Hookey Pico-Salax Timing
First Posted: April 21, 2009    Key Record Dates
Last Update Posted: August 31, 2015
Last Verified: August 2015

Additional relevant MeSH terms:
Magnesium Oxide
Citric Acid
Antacids
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Agents
Anticoagulants
Calcium Chelating Agents
Chelating Agents
Sequestering Agents